9 completed, 6 terminated, 3 recruiting, 3 withdrawn. 21 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 9, Terminated 6, Recruiting 3, Withdrawn 3 |
| Phase 1 | 7 | Completed 3, Recruiting 2, Terminated 1, Withdrawn 1 |
Follow tivozanib: new trials by email Literature Review of tivozanib trials Research Report on tivozanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma Tivozanib, Nivolumab - Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 48 | 2024-01-05 | 2026-10-07 |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers Tivozanib - Cholangiocarcinoma, Bile Duct Neoplasm | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2022-03-04 | 2026-10-16 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Tivozanib, Durvalumab - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 27 | 2019-09-30 | 2023-07-12 |
| Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC Tivozanib, Nivolumab - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Completed | AVEO Pharmaceuticals, Inc. | 28 | 2017-03-22 | 2021-12-06 |
| Tivozanib As Maintenance Therapy In GYN Tivozanib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 4 | 2013-11-01 | 2017-06-05 |
| A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation Tivozanib, Erlotinib, Standard of Care treatment - Non-small Cell Lung Cancer, Stage IV Disease | Phase 1 / Phase 2 | Withdrawn | University of Utah | 2013-11-01 | 2013-07-25 | |
| Tivozanib + Enzalutamide in Adv Prostate Cancer Tivozanib, Enzalutamide - Prostate Cancer | Phase 2 | Terminated | Massachusetts General Hospital | 5 | 2013-09-03 | 2026-05-20 |
| Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery Tivozanib (1mg), Tivozanib (1.5mg) - Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 33 | 2013-07-11 | 2020-10-28 |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Tivozanib - Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Completed | Northwestern University | 31 | 2013-06-06 | 2021-10-12 |
| Tivozanib for Recurrent Glioblastoma Tivozanib - Glioblastoma | Phase 2 | Completed | Massachusetts General Hospital | 10 | 2013-06-01 | 2019-01-08 |
| Tivozanib + Gemcitabine in Metastatic RCC Tivozanib, Gemcitabine - Renal Cell Carcinoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2013-06-01 | 2013-06-19 | |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas tivozanib, laboratory biomarker analysis - Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Completed | Northwestern University | 58 | 2013-03-06 | 2019-09-09 |
| Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer Tivozanib - Hepatocellular Cancer | Phase 2 | Terminated | Emory University | 7 | 2013-03-01 | 2016-04-22 |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer Tivozanib Hydrochloride, paclitaxel, Placebo - Triple Negative Breast Cancer | Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 30 | 2012-11-01 | 2020-10-27 |
| A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC Tivozanib, Sunitinib - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 58 | 2012-07-01 | 2020-10-27 |
| A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy Tivozanib, Bevacizumab, mFOLFOX6 - Colorectal Cancer | Phase 2 | Completed | AVEO Pharmaceuticals, Inc. | 265 | 2011-12-01 | 2015-07-08 |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma Tivozanib - Renal Cell Carcinoma | Phase 2 | Completed | AVEO Pharmaceuticals, Inc. | 105 | 2011-01-01 | 2020-10-27 |
| RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer Everolimus, Tivozanib - Gastrointestinal Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 56 | 2010-02-01 | 2017-04-13 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Renal Cell (7) · Bile Duct Neoplasms (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Cholangiocarcinoma (1) · Clear-cell metastatic renal cell carcinoma (1)
AVEO Pharmaceuticals, Inc. (7) · Dana-Farber Cancer Institute (3) · Massachusetts General Hospital (2) · Northwestern University (2) · City of Hope Medical Center (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Florida (1) · University of Utah (1)
United States (18) · Canada (3) · Italy (3) · Spain (3) · Australia (2) · Belgium (2) · France (2) · Germany (2) · Ukraine (2) · United Kingdom (2) · Austria (1) · Czechia (1) · Finland (1) · Hungary (1) · India (1)
Bassel El-Rayes, MD (1) · Brian Wolpin, MD (1) · Charles B Nguyen (1) · Daniela Matei, MD (1) · Dmitriy G Nosov, M.D. (1) · Elizabeth Gerstner, MD (1) · Eric Jonasch, M D (1) · Jonathan M Hernandez, M.D. (1) · Leighton Elliott, MD (1) · M. Dror Michaelson, MD, PhD (1) · Mark Agulnik, MD (1) · Michael Needle (1) · Michael Needle, MD (1) · Renuka Iyer (1)
PMID 23580238, PMID 27771610, PMID 32037403, PMID 33010459, PMID 33101775, PMID 33445053, PMID 34071188, PMID 36399037, PMID 36912078, PMID 37185961, PMID 37315114
P30CA016056 (1), P30CA033572 (1)